Summary

Nuclear Medicine Market Research Report Information by Type (Diagnosis [SPECT Radiopharmaceuticals {Tc99m, I-123, and Others} and PET Radiopharmaceuticals {F18, C11 Choline, and Others}] and Therapeutic (Alpha Emitters [Actinium-225 (Ac-225), Radium-223 (Ra-223), and Others], Beta Emitters [Yttrium-90 (Y-90), Lutetium-177 (Lu-177), and Others], and Brachytherapy Isotopes [Iodine-125 (I-125) and Others]), by Application (Neurology, Cardiology, Oncology [Prostate Cancer, Breast Cancer, Lung and Bronchus Cancer, Thyroid Cancer, Colorectal Cancer, and Others], and Others), by End User (Hospitals & Diagnostic Centers, Research Institutes, and Others), and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Market Overview
Nuclear Medicine Market size was valued at USD 9.84 billion in 2023. The Nuclear Medicine Market industry is projected to grow from USD 10.63 billion in 2024 to USD 27.96 billion by 2032. The factors contributing to the growth of the market are increasing applications of radioisotopes in the healthcare industry and technological advancements in nuclear medicine. Furthermore, rising public-private funding for R&D of new techniques and growing R&D in the pharmaceutical and biotechnology industry to enhance radiotherapy for proper diagnosis of diseases such as thyroid-related diseases, respiratory diseases, bone diseases, neurological diseases, and others also drives the growth of the nuclear medicine market.

Market Segment Insights
Based on type, the Nuclear Medicine Market has been segmented into diagnosis and therapeutic. Based on application, the Nuclear Medicine Market has been segmented into neurology, cardiology, oncology, and others. Based on end user, the Nuclear Medicine Market has been classified as hospitals & diagnostic centers, research institutes, and others.

Regional Insights
By region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America accounted for the largest market share of 42.42% in 2023 owing to the presence of active industry players in the region and the availability of the products propelling the market's growth in North America. Europe is anticipated to witness significant growth during the forecast period due to increasing number of people suffering from heart illness, Alzheimer's disease, and neurological problems, rising expenditure, and increased need for better diagnostic and treatment processes are all propelling the growth in the European market. Furthermore, the nuclear medicine market is growing due to the adoption of improved radiopharmaceuticals, new launches, and acquisitions and mergers. The growth of the market in Asia-Pacific is predicted to rise rapidly due to an increase in the number of cardiac patients and improved imaging techniques using diagnostic equipment such as PET and SPECT. Furthermore, getting multiple 2D and 3D images obtained by performing SPECT imaging techniques with the help of a gamma camera aids in better access for physicians is driving the region’s nuclear medicine market forward. Moreover, Japan nuclear medicine market held the largest market share in 2023 and India nuclear medicine market is the fastest growing market in the Asia-Pacific region.

Major Players
Key Companies in the Nuclear Medicine Market includes Novartis AG (Switzerland), GE Healthcare (US), Cardinal Health (US), Eckert & Ziegler Group (Germany), Lantheus (US), Jubilant Radiopharma (Canada), Bayer AG (Germany), Siemens Healthineers (Germany), Curium Pharma (France), Bracco (Italy), and Others.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
3.5.1 PRIMARY RESEARCH DATA FLOW:
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
3.8.1 MICROECONOMIC FACTOR ANALYSIS:
3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 RISING PREVALENCE OF CANCER AND OTHER CHRONIC DISEASES
4.2.2 TECHNOLOGICAL ADVANCEMENTS IN NUCLEAR MEDICINE
4.3 RESTRAINTS
4.3.1 SHORT HALF-LIFE OF RADIOPHARMACEUTICALS
4.3.2 SHORTAGE OF TRAINED MEDICAL PERSONNEL
4.4 OPPORTUNITY
4.4.1 USE OF RADIOPHARMACEUTICALS IN NEUROLOGICAL APPLICATIONS
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 THREAT OF SUBSTITUTES
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL NUCLEAR MEDICINE MARKET
6 GLOBAL NUCLEAR MEDICINE MARKET, BY TYPE
6.1 OVERVIEW
6.2 DIAGNOSTIC
6.2.1 SPECT RADIOPHARMACEUTICALS
6.2.1.1 MO99/TC99M
6.2.1.2 I-123
6.2.1.3 OTHERS
6.2.2 PET RADIOPHARMACEUTICALS
6.2.2.1 F18
6.2.2.2 C11 CHOLINE
6.2.2.3 OTHERS
6.3 THERAPEUTIC
6.3.1 ALPHA EMITTERS
6.3.1.1 ACTINIUM-225 (AC-225)
6.3.1.2 RADIUM-223 (RA-223)
6.3.1.3 OTHERS
6.3.2 BETA EMITTERS
6.3.2.1 YTTRIUM-90 (Y-90)
6.3.2.2 LUTETIUM-177 (LU-177)
6.3.2.3 OTHERS
6.3.3 BRACHYTHERAPY ISOTOPE
6.3.3.1 IODINE-125 (I-125)
6.3.3.2 OTHERS
7 GLOBAL NUCLEAR MEDICINE MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 NEUROLOGY
7.3 CARDIOLOGY
7.4 ONCOLOGY
7.4.1 PROSTATE CANCER
7.4.2 BREAST CANCER
7.4.3 LUNG AND BRONCHUS CANCER
7.4.4 THYROID CANCER
7.4.5 COLORECTAL CANCER
7.4.6 OTHERS
7.5 OTHERS
8 GLOBAL NUCLEAR MEDICINE MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS AND DIAGNOSTIC CENTERS
8.3 RESEARCH INSTITUTES
8.4 OTHERS
9 GLOBAL NUCLEAR MEDICINE MARKET, BY REGION
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.2.3 MEXICO
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE
9.3.3 UK
9.3.4 ITALY
9.3.5 SPAIN
9.3.6 REST OF EUROPE
9.4 ASIA-PACIFIC
9.4.1 CHINA
9.4.2 INDIA
9.4.3 JAPAN
9.4.4 SOUTH KOREA
9.4.5 AUSTRALIA
9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
9.5.1 MIDDLE EAST & AFRICA
9.5.2 SOUTH AMERICA
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS, 2023
10.3 COMPETITOR DASHBOARD
10.4 PUBLIC PLAYERS STOCK SUMMARY
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL
10.6.2 PARTNERSHIP
10.6.3 ACQUISITION
10.6.4 AGREEMENT
10.6.5 COLLABORATION
10.6.6 EXPANSION
11 COMPANY PROFILES
11.1 GE HEALTHCARE
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS/SERVICES OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 CARDINAL HEALTH
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 CURIUM
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 KEY STRATEGIES
11.4 NOVARTIS AG
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.4.6 KEY STRATEGIES
11.5 LANTHEUS
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 KEY STRATEGIES
11.6 JUBILANT RADIOPHARMA
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 KEY STRATEGIES
11.7 SIEMENS HEALTHINEERS
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.7.6 KEY STRATEGIES
11.8 BAYER AG
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.8.6 KEY STRATEGY
11.9 ECKERT & ZIEGLER
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIES
11.10 BRACCO
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCTS OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGY
12 DATA CITATIONS